In Brief: Lasermedics
This article was originally published in The Gray Sheet
Lasermedics: Acquires exclusive worldwide rights to manufacture, market and distribute CB Svendsen's MicroLight 830 low-level laser used for the treatment of Carpel Tunnel Syndrome. The laser is currently in U.S. clinical trials under an FDA investigational device exemption. Marketing and distribution rights were granted for a one-time payment and quarterly royalty payments based on sales over the next seven years, after which Lasermedics will have sole-ownership of the technology. Manufacturing rights were granted for a one-time payment due in June 1998. Under a separate agreement CB Svendsen will continue to manufacture the laser for Lasermedics for the international market...
You may also be interested in...
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.